Stock TRVI TREVI THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Trevi Therapeutics, Inc.

Equities

TRVI

US89532M1018

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
2.57 USD -0.77% Intraday chart for Trevi Therapeutics, Inc. +2.80% +91.79%
May. 07 Transcript : Trevi Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024
May. 07 Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Trevi Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio? for Chronic Cough in Idiopathic Pulmonary Fibrosis
CI
Trevi Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio?? for Refractory Chronic Cough
CI
Trevi Therapeutics, Inc. Announces Results from Phase 2b/3 Prism Open-Label Extension Study of Haduvio in Prurigo Nodularis
CI
Trevi Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
TREVI THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
Trevi Therapeutics Gets Patent Notice of Allowance for Method to Treat Chronic Cough in Idiopathic Pulmonary Fibrosis
MT
Trevi Therapeutics, Inc. Announces Allowance for U.S. Patent Application Covering Use of Haduvio (Nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
CI
Earnings Flash (TRVI) TREVI THERAPEUTICS Reports Q3 Loss $-0.12
MT
TREVI THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
Trevi Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
CI
TREVI THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
Trevi Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Earnings Flash (TRVI) TREVI THERAPEUTICS Reports Q2 Loss $-0.14
MT
Trevi Therapeutics Inc. Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvi in Treatment of Prurigo Nodularis
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRVI Stock
  4. News Trevi Therapeutics, Inc.
  5. Highlights